
David H. Ilson, MD, PhD - Up Close and Personalizing Gastric Cancer Care: Precision Medicine With HER2-Targeted Therapies and Other Novel Agents
08/13/20 • 67 min
Previous Episode

Harry P. Erba, MD, PhD - Transforming Modern Care in AML: Clinical Solutions With Novel Agents for Diverse Patient Populations
Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.
Next Episode

John C. Byrd, MD - How I Think, How I Treat: BTK Inhibitors as a Centerpiece of Care for Hematologic Cancers
Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/peerview-heart-lung-and-blood-cmecnecpe-video-podcast-25504/david-h-ilson-md-phd-up-close-and-personalizing-gastric-cancer-care-pr-6680937"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to david h. ilson, md, phd - up close and personalizing gastric cancer care: precision medicine with her2-targeted therapies and other novel agents on goodpods" style="width: 225px" /> </a>
Copy